Abstract:Purpose: Thalidomide has demonstrated clinical activity in various malignancies including androgen-independent prostate cancer. The development of novel thalidomide analogs with better activity/toxicity profiles is an ongoing research effort. Our laboratory previously reported the in vitro antiangiogenic activity of the N-substituted thalidomide analog CPS11 and the tetrafluorinated analogs CPS45 and CPS49. The current study evaluated the therapeutic potential of these analogs in the treatment of prostate canc… Show more
“…The antitumor activity is similar to that seen with prostate cancer cell lines, where treatment with CPS11 and CPS49 has led to regression of subcutaneous implanted tumors in SCID mice. 13 Although CPS11 was more potent than CPS49 against prostate cancer, our findings suggest that CPS49 is more potent in the setting of MM.…”
Section: Discussionmentioning
confidence: 64%
“…7 CPS49 can decrease intratumoral vascularity in xenograft models of prostate cancer via inhibition of PDGF. 13 Ongoing studies in animal models of MM will evaluate whether antiangiogenesis correlates with MM responses. Finally, immunomodulation contributes to the anti-MM activity of thalidomide and many of its analogs, 20 and ongoing studies are evaluating the effects of CPS11 and CPS49 on NK and T cells.…”
“…The antitumor activity is similar to that seen with prostate cancer cell lines, where treatment with CPS11 and CPS49 has led to regression of subcutaneous implanted tumors in SCID mice. 13 Although CPS11 was more potent than CPS49 against prostate cancer, our findings suggest that CPS49 is more potent in the setting of MM.…”
Section: Discussionmentioning
confidence: 64%
“…7 CPS49 can decrease intratumoral vascularity in xenograft models of prostate cancer via inhibition of PDGF. 13 Ongoing studies in animal models of MM will evaluate whether antiangiogenesis correlates with MM responses. Finally, immunomodulation contributes to the anti-MM activity of thalidomide and many of its analogs, 20 and ongoing studies are evaluating the effects of CPS11 and CPS49 on NK and T cells.…”
“…Recent reports examined to demonstrate the possibility to using gamma-oryzanol to treat cancer including prostate cancer (Ng and Figg, 2003). The imbalance of oxidant-antioxidant system resulting in increased oxidative stress was reported as an important feature of this type of cancer (Battisti et al, 2011;Tangjitjaroenkun et al, 2012).…”
Background: To assess the antioxidant effects of gamma-oryzanol on human prostate cancer cells. Materials and Methods: Cytotoxic activity of gamma-oryzanol on human DU145 and PC3 prostate cancer cells was determined by proliferation assay using 3-(4, 5-dimethylthiazol, 2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) reagent. mRNA levels of genes involved in the intracellular antioxidant system, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and glutathione reductase (GSR) were determined by reverse transcription-polymerase chain reaction (RT-PCR). Cancer cell lysates were used to measure lipid peroxidation using thiobarbituric acid reactive substance (TBARS). Glutathione contents of the cell lysates were estimated by the reaction between sulfhydryl group of 5, 5'-dithio (bis) nitrobenzoic acid (DTNB) to produce a yellowcolor of 5-thio-2-nitrobenzoic acid using colorimetric assay. Catalase activity was also analysed by examining peroxidative function. Protein concentration was estimated by Bradford's assay. Results: All concentrations of gamma-oryzanol, 0.1-2.0mg/ml, significantly inhibited cell growth in a dose-and time-dependent fashion in both prostate cancer cell lines, DU145 and PC3. Gene expression of catalase in DU145 and PC3 exposed to gamma-orizanol at 0.5mg/ml for 14 days was down regulated, while mRNA of GPX was also down regulated in PC3. The MDA and glutathione levels including catalase activity in the cell lysates of DU145 and PC3 treated with gamma-oryzanol 0.1 and 0.5mg/ml were generally decreased. Conclusions: This study highlighted effects of gamma-oryzanol via the down-regulation of antioxidant genes, catalase and GPX, not cytotoxic roles. This might be interesting for adjuvant chemotherapy to make prostate cancer cells more sensitive to free radicals. It might be useful for the reduction of cytotoxic agents and cancer chemoprevention.
“…Therefore, it was proposed that licorice could cause the deficiency of serum testosterone, leading to sexual dysfunction or decline of libido in men [1,2]. However, the testosterone-reducing effect of licorice in males is controversial, since the results of Armanini et al [1,2] have not been reproduced by other investigators [16,25].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.